Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Osteoporosis

Free Subscription Articles published in J Clin Endocrinol Metab Retrieve available abstracts of 99 articles: HTML format

Single Articles

July 2026
1. BADOUR S, McCoy RG, Takagi M, Everhart AO, et al
   Timeliness of antiresorptive consolidation after anabolic therapy for primary fracture prevention: A US cohort study.
   J Clin Endocrinol Metab. 2026;111:2320-2331.
   PubMed     Abstract available
   
   
   
2. VILACA T, Eastell R
   Imminent fracture risk: contributing mechanisms, risk assessment and implications for treatment.
   J Clin Endocrinol Metab. 2026 Jul 14:dgag278. doi: 10.1210.
   PubMed     Abstract available
   
   
   
3. 
   Correction to: "Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case Cohort Study with Blinded Radiographic Review".
   J Clin Endocrinol Metab. 2026 Jul 10:dgag267. doi: 10.1210.
   PubMed    
   
   
   June 2026
4. WOODS G, Wooldridge J, Weaver CM, Giangregorio L, et al
   Approach to Personalizing the Treatment of Osteoporosis.
   J Clin Endocrinol Metab. 2026 Jun 27:dgag257. doi: 10.1210.
   PubMed     Abstract available
   
   
   April 2026
5. DIAS JP, Dobs AS
   Will Selective Androgen Receptor Modulators Ever Reach The Clinic?
   J Clin Endocrinol Metab. 2026;111:e1467-e1471.
   PubMed     Abstract available
   
   
   
6. KITAMURA Y, Yokomoto-Umakoshi M, Nakano Y, Nakatani K, et al
   Inflammatory Markers Link Steroid Profiles to Bone Status in Patients with Autonomous Cortisol Secretion.
   J Clin Endocrinol Metab. 2026;111:1299-1310.
   PubMed     Abstract available
   
   
   
7. TOURNIS S, Kassi E, Palermo A, Yavropoulou MP, et al
   Approach to the Patient: Management of bone fragility in patients with chronic hypoparathyroidism.
   J Clin Endocrinol Metab. 2026 Apr 11:dgag160. doi: 10.1210.
   PubMed     Abstract available
   
   
   March 2026
8. BOLLAND MJ, Nisa Z, Mellar A, Gasteiger C, et al
   Antifracture Efficacy of 5- or 10-Yearly Zoledronate in Women Aged 50 to 60 Years: Secondary Analyses of a Randomized Trial.
   J Clin Endocrinol Metab. 2026;111:e1080-e1087.
   PubMed     Abstract available
   
   
   February 2026
9. OLIVERI C, Xourafa A, Morabito N, Gaudio A, et al
   Statins Do Not Affect Bone Anabolism in Older Women Treated With Teriparatide.
   J Clin Endocrinol Metab. 2026;111:e691-e696.
   PubMed     Abstract available
   
   
   
10. OKA P, Moosa AS, Koh EYL, Ng CJ, et al
    Health and adverse events associated with extended oral bisphosphonates among postmenopausal women: a systematic review.
    J Clin Endocrinol Metab. 2026 Feb 10:dgag057. doi: 10.1210.
    PubMed     Abstract available
    
    
    
11. LIU Y, Walzer D, Schmitz S, Shukla AP, et al
    Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures.
    J Clin Endocrinol Metab. 2026 Feb 7:dgag052. doi: 10.1210.
    PubMed     Abstract available
    
    
    January 2026
12. TSOURDI E
    Predicting bone fragility in perimenopause: Results from the SWAN Study.
    J Clin Endocrinol Metab. 2026 Jan 10:dgag004. doi: 10.1210.
    PubMed    
    
    
    December 2025
13. SHIEH A, Karlamangla AS, Gossiel F, Eastell R, et al
    Anti-Mullerian Hormone and Collagen Type I C-telopeptide Predict Fast, Imminent Bone Loss in Early Perimenopause: SWAN.
    J Clin Endocrinol Metab. 2025 Dec 16:dgaf658. doi: 10.1210.
    PubMed     Abstract available
    
    
    November 2025
14. 
    Correction to:?"Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline".
    J Clin Endocrinol Metab. 2025 Nov 28:dgaf645. doi: 10.1210.
    PubMed    
    
    
    
15. LANGDAHL BL, Laursen NA, Makinen V, Harslof T, et al
    Approach to the patient - Transitions in Osteoporosis Therapy.
    J Clin Endocrinol Metab. 2025 Nov 17:dgaf614. doi: 10.1210.
    PubMed     Abstract available
    
    
    
16. PRASAD TN, Pal R, Bhadada SK, Ram S, et al
    Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial.
    J Clin Endocrinol Metab. 2025 Nov 3:dgaf589. doi: 10.1210.
    PubMed     Abstract available
    
    
    September 2025
17. SZULC P
    Fragility index in randomized clinical trials on osteoporosis.
    J Clin Endocrinol Metab. 2025 Sep 6:dgaf505. doi: 10.1210.
    PubMed    
    
    
    August 2025
18. DICKENS LT, Abe CM, Connors M, Osman F, et al
    Osteoporosis Epidemiology, Diagnosis, and Management Across Race and Ethnicity in the United States.
    J Clin Endocrinol Metab. 2025 Aug 18:dgaf466. doi: 10.1210.
    PubMed     Abstract available
    
    
    July 2025
19. HASEBE M, Su CY
    Letter to the Editor from Hasebe and Su: "Adrenalectomy Reduces the Risk of Vertebral Fractures in Patients With Mild Autonomous Cortisol Secretion".
    J Clin Endocrinol Metab. 2025 Jul 2:dgaf384. doi: 10.1210.
    PubMed    
    
    
    
20. FAVERO V, Chiodini I
    Response to Letter to the Editor from Hasebe and Su: "Adrenalectomy Reduces the Risk of Vertebral Fractures in Patients With Mild Autonomous Cortisol Secretion".
    J Clin Endocrinol Metab. 2025 Jul 2:dgaf385. doi: 10.1210.
    PubMed    
    
    
    June 2025
21. 
    Correction to: "Effective Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis".
    J Clin Endocrinol Metab. 2025 Jun 24:dgaf354. doi: 10.1210.
    PubMed    
    
    
    
22. TENUTA M, Hasenmajer V, Gianfrilli D, Isidori AM, et al
    Testosterone and Male Bone Health: A Puzzle of Interactions.
    J Clin Endocrinol Metab. 2025;110:e2121-e2135.
    PubMed     Abstract available
    
    
    
23. HE JH, Bennett WL, Ma J, Oyeka CP, et al
    Sex Hormones Mediate Intensive Lifestyle Intervention-Induced Bone Mineral Density Changes: Look AHEAD Sex Hormone Study.
    J Clin Endocrinol Metab. 2025 Jun 17:dgaf359. doi: 10.1210.
    PubMed     Abstract available
    
    
    
24. MUNOZ-PARDEZA J, Gracia-Marco L, Lopez-Gil JF, Hormazabal-Aguayo I, et al
    The role of muscular fitness on bone mineral content and areal bone mineral density in youth with type 1 diabetes.
    J Clin Endocrinol Metab. 2025 Jun 5:dgaf328. doi: 10.1210.
    PubMed     Abstract available
    
    
    May 2025
25. KLUIJVER LG, Wagenmakers MAEM, Wilson JHP, Langendonk JG, et al
    The Impact of Minimal Sunlight Exposure on Bone Health: Insights From a Cohort Study in Erythropoietic Protoporphyria.
    J Clin Endocrinol Metab. 2025;110:1633-1646.
    PubMed     Abstract available
    
    
    
26. BIOLETTO F, Pusterla A, Fraire F, Sauro L, et al
    Sex-specific Association of Chronic Proton Pump Inhibitor Use With Reduced Bone Density and Quality.
    J Clin Endocrinol Metab. 2025;110:e2071-e2079.
    PubMed     Abstract available
    
    
    April 2025
27. MORELLI V, Favero V, Frigerio S, Aresta C, et al
    Adrenalectomy reduces the risk of vertebral fractures in patients with mild autonomous cortisol secretion.
    J Clin Endocrinol Metab. 2025 Apr 11:dgaf227. doi: 10.1210.
    PubMed     Abstract available
    
    
    
28. ZOULAKIS M, Axelsson KF, Litsne H, Johansson L, et al
    Bone Marrow Adiposity Assessed by HRpQCT Is Related to Fracture Risk and Bone Mineral Density in Older Swedish Women.
    J Clin Endocrinol Metab. 2025 Apr 3:dgaf216. doi: 10.1210.
    PubMed     Abstract available
    
    
    
29. HOLLEY M, Razvi S, Maxwell I, Dew R, et al
    Assessing the Cardiovascular Effects of Levothyroxine Use in an Ageing United Kingdom population (ACEL-UK): Cohort Study.
    J Clin Endocrinol Metab. 2025 Apr 3:dgaf208. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2025
30. ZEMEL BS, Winer KK, Kelly A, Freedman DS, et al
    Race-Neutral Pediatric Reference Ranges for Bone Mineral Density Predict Prospective Fractures in Childhood.
    J Clin Endocrinol Metab. 2025 Mar 25:dgaf183. doi: 10.1210.
    PubMed     Abstract available
    
    
    
31. NILSSON M, Akesson KE, Thier M, Nordenstrom E, et al
    Response to "Letter to the Editor from Candemir and Cakal: [24-hour Urine Calcium Predicts Reduced Fracture Incidence and Improved Bone Mineral Density After Surgery for Primary Hyperparathyroidism]".
    J Clin Endocrinol Metab. 2025 Mar 6:dgaf127. doi: 10.1210.
    PubMed    
    
    
    
32. CANDEMIR B, Cakal E
    "Letter to the Editor from Candemir and Cakal: [24-hour Urine Calcium Predicts Reduced Fracture Incidence and Improved Bone Mineral Density After Surgery for Primary Hyperparathyroidism]".
    J Clin Endocrinol Metab. 2025 Mar 6:dgaf126. doi: 10.1210.
    PubMed    
    
    
    February 2025
33. UEHARA A, Mok Y, Matsushita K, Lutsey PL, et al
    Serum Sodium, Potassium, Magnesium, Calcium, and Phosphorus Levels and Risk of Fracture in the Community.
    J Clin Endocrinol Metab. 2025 Feb 26:dgaf120. doi: 10.1210.
    PubMed     Abstract available
    
    
    
34. STANCAMPIANO MR, Pitea M, Maruca K, Meroni SLC, et al
    Bone mineral density in patients with congenital adrenal hyperplasia from prepubertal to adult age.
    J Clin Endocrinol Metab. 2025 Feb 25:dgaf123. doi: 10.1210.
    PubMed     Abstract available
    
    
    
35. BIOLETTO F, Sibilla M, Berton AM, Prencipe N, et al
    Mild Hyponatremia Is Not Associated With Degradation of Trabecular Bone Microarchitecture Despite Bone Mass Loss.
    J Clin Endocrinol Metab. 2025;110:e774-e782.
    PubMed     Abstract available
    
    
    
36. PAPADOPOULOU-MARKETOU N, Papageorgiou A, Marketos N, Tsiamyrtzis P, et al
    Effective Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis.
    J Clin Endocrinol Metab. 2025 Feb 7:dgaf077. doi: 10.1210.
    PubMed     Abstract available
    
    
    January 2025
37. FERRARI S, Betah D, Feldman RG, Langdahl BL, et al
    Romosozumab Improves Tissue Thickness-Adjusted Trabecular Bone Score in Women With Osteoporosis and Diabetes.
    J Clin Endocrinol Metab. 2025 Jan 24:dgae862. doi: 10.1210.
    PubMed     Abstract available
    
    
    
38. EVERHART AO, Brito JP, Clarke BL, Herrin J, et al
    Trends in Osteoporosis Drug Therapy Receipt Among Commercial and Medicare Advantage Enrollees in the United States, 2011-2022.
    J Clin Endocrinol Metab. 2025 Jan 15:dgae840. doi: 10.1210.
    PubMed     Abstract available
    
    
    
39. IMANISHI Y, Imai T, Fujii H, Aida R, et al
    Eldecalcitol Add-On to Risedronate Reduces Bone Loss from Aromatase Inhibitors in Postmenopausal Breast Cancer Patients.
    J Clin Endocrinol Metab. 2025 Jan 15:dgaf019. doi: 10.1210.
    PubMed     Abstract available
    
    
    December 2024
40. 
    Correction to: "Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study".
    J Clin Endocrinol Metab. 2024 Dec 17:dgae870. doi: 10.1210.
    PubMed    
    
    
    
41. KONG SH, Park JY, Shin MK, Lee HJ, et al
    Effectiveness of Bisphosphonates in Young Adults with Fragility Fractures: Representative Population-Based Cohort Study.
    J Clin Endocrinol Metab. 2024 Dec 6:dgae850. doi: 10.1210.
    PubMed     Abstract available
    
    
    
42. HANSEN BB, Hass Rubin K, Vind Nielsen C, Frost Nielsen M, et al
    Biological Heterogeneity in Susceptibility to Glucocorticoid-Induced Bone Loss: Short- and Long-Term Hip BMD Trajectories.
    J Clin Endocrinol Metab. 2024 Dec 3:dgae832. doi: 10.1210.
    PubMed     Abstract available
    
    
    November 2024
43. BURDEN AM, Martinez-De la Torre A, Burkard T, Immoos M, et al
    Increased risk of fracture among patients with iron overload: a population-based matched cohort study.
    J Clin Endocrinol Metab. 2024 Nov 18:dgae807. doi: 10.1210.
    PubMed     Abstract available
    
    
    
44. KAWAZOE M, Kaneko K, Masuoka S, Yamada S, et al
    Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy.
    J Clin Endocrinol Metab. 2024 Nov 18:dgae810. doi: 10.1210.
    PubMed     Abstract available
    
    
    
45. BLANDIN C, Collet C, Ostertag A, Funck-Brentano T, et al
    Genetics and bone mineral density predict the fractures in adults with osteogenesis imperfecta: a prospective study.
    J Clin Endocrinol Metab. 2024 Nov 8:dgae791. doi: 10.1210.
    PubMed     Abstract available
    
    
    
46. WANG B, Dhaliwal R, Ewing SK, Schwartz AV, et al
    F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes.
    J Clin Endocrinol Metab. 2024 Nov 8:dgae788. doi: 10.1210.
    PubMed     Abstract available
    
    
    October 2024
47. NORDSTROM P, Ballin M, Nordstrom A
    Associations between Balance Measures and Risk of Fractures in 70-Year-Old Individuals: A Population-Based Cohort Study.
    J Clin Endocrinol Metab. 2024 Oct 29:dgae766. doi: 10.1210.
    PubMed     Abstract available
    
    
    
48. SHA L, Zhang L, Zhao X, Xiang R, et al
    Shared Genetic Architecture and Causal Relationship between Serum 25-Hydroxyvitamin D and Bone Mineral Density.
    J Clin Endocrinol Metab. 2024 Oct 21:dgae738. doi: 10.1210.
    PubMed     Abstract available
    
    
    
49. KHOSLA S
    The Complex Interplay of Sex Steroids and Sex Hormone-binding Globulin in Determining Fracture Risk in Men.
    J Clin Endocrinol Metab. 2024 Oct 18:dgae742. doi: 10.1210.
    PubMed    
    
    
    
50. WANG S, Yu EW, Hivert MF, Rifas-Shiman SL, et al
    Associations of AMH in mid-reproductive years with bone mineral density and turnover markers in mid-life.
    J Clin Endocrinol Metab. 2024 Oct 17:dgae694. doi: 10.1210.
    PubMed     Abstract available
    
    
    
51. CAULEY JA, Lui LY, LeBoff MS, Watts NB, et al
    New Challenges: Use and Interpretation of Radius Bone Mineral Density.
    J Clin Endocrinol Metab. 2024 Oct 15:dgae726. doi: 10.1210.
    PubMed     Abstract available
    
    
    
52. SUN X, Bolster MB, Leder BZ, Fan W, et al
    Dose-specific effects of denosumab on serum calcium levels in patients with osteoporosis and various renal functions.
    J Clin Endocrinol Metab. 2024 Oct 11:dgae721. doi: 10.1210.
    PubMed     Abstract available
    
    
    
53. PEPE J, Colangelo L, Diacinti D, Angelozzi M, et al
    Association between radius axial low-frequency ultrasound velocity and bone fragility in primary hyperparathyroidism.
    J Clin Endocrinol Metab. 2024 Oct 4:dgae695. doi: 10.1210.
    PubMed     Abstract available
    
    
    September 2024
54. MOTLAGHZADEH Y, Wu JY
    Approach to Bone Health in the Patient With Breast Cancer.
    J Clin Endocrinol Metab. 2024;109:e1902-e1910.
    PubMed     Abstract available
    
    
    
55. LANGDAHL B, Chung YS, Plebanski R, Czerwinski E, et al
    Proposed Denosumab Biosimilar SB16 vs Reference Denosumab in Postmenopausal Osteoporosis: Phase 3 Results Up to Month 12.
    J Clin Endocrinol Metab. 2024 Sep 7:dgae611. doi: 10.1210.
    PubMed     Abstract available
    
    
    August 2024
56. WARD LM, Bakhamis S, Koujok K
    Approach to the Pediatric Patient with Glucocorticoid-Induced Osteoporosis.
    J Clin Endocrinol Metab. 2024 Aug 10:dgae507. doi: 10.1210.
    PubMed     Abstract available
    
    
    July 2024
57. HARTZ MC, Johannessen FB, Harslof T, Langdahl BL, et al
    The Effectiveness and Safety of Romosozumab and Teriparatide in Postmenopausal Women with Osteoporosis.
    J Clin Endocrinol Metab. 2024 Jul 16:dgae484. doi: 10.1210.
    PubMed     Abstract available
    
    
    
58. ZHOU Z, Xu H, Fu J, Wei P, et al
    Urolithiasis Causes Osteoporosis in Asians: Genetic Evidence from Mendelian Randomization and Pathway Analysis.
    J Clin Endocrinol Metab. 2024 Jul 8:dgae461. doi: 10.1210.
    PubMed     Abstract available
    
    
    June 2024
59. TSOURDI E
    Drug holidays with bisphosphonates in osteoporosis treatment: one size does not fit all.
    J Clin Endocrinol Metab. 2024 Jun 26:dgae438. doi: 10.1210.
    PubMed    
    
    
    May 2024
60. TSAI YL, Chuang YC, Cheng YY, Deng YL, et al
    Low Bone Mineral Density as a Predictor of Mortality and Infections in Stroke Patients: A Hospital-based Study.
    J Clin Endocrinol Metab. 2024 May 25:dgae365. doi: 10.1210.
    PubMed     Abstract available
    
    
    
61. STOKAR J, Szalat A
    Response to Letter to the Editor from Kawaguchi: 'Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study.
    J Clin Endocrinol Metab. 2024 May 20:dgae348. doi: 10.1210.
    PubMed    
    
    
    
62. KAWAGUCHI H
    Letter to the Editor from Kawaguchi: 'Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study'.
    J Clin Endocrinol Metab. 2024 May 18:dgae347. doi: 10.1210.
    PubMed    
    
    
    April 2024
63. 
    Correction to: "Increased Risk of Vertebral Fractures in Patients With Mild Autonomous Cortisol Secretion".
    J Clin Endocrinol Metab. 2024 Apr 22:dgae246. doi: 10.1210.
    PubMed    
    
    
    
64. LEUNG MTY, Turner JP, Marquina C, Ilomaki J, et al
    Impact of oral bisphosphonate drug holiday on mortality following hip fracture: a population-based cohort study.
    J Clin Endocrinol Metab. 2024 Apr 17:dgae272. doi: 10.1210.
    PubMed     Abstract available
    
    
    
65. KAMANDA-KOSSEH M, Shiau S, Agarwal S, Kondapalli A, et al
    Bisphosphonates Maintain BMD after Sequential Teriparatide and Denosumab in Premenopausal Women with Idiopathic Osteoporosis.
    J Clin Endocrinol Metab. 2024 Apr 12:dgae240. doi: 10.1210.
    PubMed     Abstract available
    
    
    
66. ZHANG X, Cheung KS, Mak LY, Tan KCB, et al
    Low Bone Mineral Density as a Risk Factor for Liver Cirrhosis: A Prospective Cohort Study.
    J Clin Endocrinol Metab. 2024 Apr 4:dgae223. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2024
67. HE D, Liu H, Zhao Y, Wei W, et al
    Assessing the interaction effects of mitochondrial DNA polymorphisms and lifestyle on heel bone mineral density.
    J Clin Endocrinol Metab. 2024 Mar 27:dgae195. doi: 10.1210.
    PubMed     Abstract available
    
    
    
68. STOKAR J, Szalat A
    Cardiovascular Safety of Romosozumab vs. PTH Analogs for Osteoporosis Treatment: a Propensity Score Matched Cohort Study.
    J Clin Endocrinol Metab. 2024 Mar 14:dgae173. doi: 10.1210.
    PubMed     Abstract available
    
    
    February 2024
69. TRAMONTANA F, Napoli N, Litwack-Harrison S, Bauer DC, et al
    More rapid bone mineral density loss in older men with diabetes: The Osteoporotic Fractures in Men (MrOS) Study.
    J Clin Endocrinol Metab. 2024 Feb 26:dgae045. doi: 10.1210.
    PubMed     Abstract available
    
    
    
70. MORI Y, Mori N
    Letter to the Editor From Mori and Mori: "Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis".
    J Clin Endocrinol Metab. 2024 Feb 9:dgae083. doi: 10.1210.
    PubMed    
    
    
    January 2024
71. MINISOLA S, Cipriani C, Colangelo L, Pepe J, et al
    At the Intersection Between Skeletal and Hematopoietic Systems: Incorporating Hemoglobin in FRAX(R).
    J Clin Endocrinol Metab. 2024;109:e856-e857.
    PubMed    
    
    
    
72. BAUER DC, Black DM, Dell R, Fan B, et al
    Bisphosphonate Use and Risk of Atypical Femoral Fractures: A Danish Case Cohort Study with Blinded Radiographic Review.
    J Clin Endocrinol Metab. 2024 Jan 10:dgae023. doi: 10.1210.
    PubMed     Abstract available
    
    
    December 2023
73. STYRKARSDOTTIR U, Tragante V, Stefansdottir L, Thorleifsson G, et al
    Obesity variants in the GIPR gene do not associate with risk of fracture or bone mineral density.
    J Clin Endocrinol Metab. 2023 Dec 20:dgad734. doi: 10.1210.
    PubMed     Abstract available
    
    
    
74. PRINCE RL
    New Data on the Increased hip Fracture Risk in Type 2 Diabetes and Its Reduction in Those With High Physical Activity.
    J Clin Endocrinol Metab. 2023 Dec 14:dgad712. doi: 10.1210.
    PubMed    
    
    
    November 2023
75. WANG M, Seibel MJ
    Approach to the Patient With Bone Fracture: Making the First Fracture the Last.
    J Clin Endocrinol Metab. 2023;108:3345-3352.
    PubMed     Abstract available
    
    
    October 2023
76. ZHANG X, Chen X, Li S, Gao M, et al
    Association between advanced glycation end products and sarcopenia: The mediating role of osteoporosis.
    J Clin Endocrinol Metab. 2023 Oct 31:dgad640. doi: 10.1210.
    PubMed     Abstract available
    
    
    September 2023
77. FAVERO V, Eller-Vainicher C, Morelli V, Cairoli E, et al
    Increased risk of vertebral fractures in patients with mild autonomous cortisol secretion.
    J Clin Endocrinol Metab. 2023 Sep 21:dgad560. doi: 10.1210.
    PubMed     Abstract available
    
    
    
78. ANAGNOSTIS P, Lampropoulou-Adamidou K, Bosdou JK, Trovas G, et al
    Comparative effectiveness of therapeutic interventions in pregnancy and lactation-associated osteoporosis: a systematic review and meta-analysis.
    J Clin Endocrinol Metab. 2023 Sep 14:dgad548. doi: 10.1210.
    PubMed     Abstract available
    
    
    August 2023
79. FLOKAS ME, Wakim P, Kollender S, Sinaii N, et al
    Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia.
    J Clin Endocrinol Metab. 2023 Aug 29:dgad514. doi: 10.1210.
    PubMed     Abstract available
    
    
    
80. RAMCHAND SK, Leder BZ
    Sequential Therapy for the Long-Term Treatment of Postmenopausal Osteoporosis.
    J Clin Endocrinol Metab. 2023 Aug 23:dgad496. doi: 10.1210.
    PubMed     Abstract available
    
    
    
81. PHUNG K, McAdam L, Ma J, McMillan HJ, et al
    Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy.
    J Clin Endocrinol Metab. 2023 Aug 23:dgad435. doi: 10.1210.
    PubMed     Abstract available
    
    
    
82. SZULC P, Lewis JR, Chapurlat R
    Accelerated bone loss in older men with severe abdominal aortic calcification - the prospective MINOS study.
    J Clin Endocrinol Metab. 2023 Aug 23:dgad459. doi: 10.1210.
    PubMed     Abstract available
    
    
    
83. CHILOIRO S, Frara S, Gagliardi I, Bianchi A, et al
    Cholecalciferol use is associated with a decreased risk of incident morphometric vertebral fractures in acromegaly.
    J Clin Endocrinol Metab. 2023 Aug 22:dgad493. doi: 10.1210.
    PubMed     Abstract available
    
    
    
84. SOTO-PEDRE E, Lin YY, Soto-Hernaez J, Newey PJ, et al
    Morbidity Associated With Primary Hyperparathyroidism-A Population-based Study With a Subanalysis on Vitamin D.
    J Clin Endocrinol Metab. 2023;108:e842-e849.
    PubMed     Abstract available
    
    
    
85. LIN SY, Chen WJ, Ku CK, Chen YM, et al
    Treatment Persistence and Medication Switch Associated with Subsequent Fractures after Osteoporotic Fractures.
    J Clin Endocrinol Metab. 2023 Aug 1:dgad449. doi: 10.1210.
    PubMed     Abstract available
    
    
    July 2023
86. LABAYEN I, Cadenas-Sanchez C, Idoate F, Medrano M, et al
    Liver fat, bone marrow adipose tissue and bone mineral density in children with overweight.
    J Clin Endocrinol Metab. 2023 Jul 25:dgad429. doi: 10.1210.
    PubMed     Abstract available
    
    
    
87. CAPPOLA AR, Auchus RJ, El-Hajj Fuleihan G, Handelsman DJ, et al
    Hormones and Aging: An Endocrine Society Scientific Statement.
    J Clin Endocrinol Metab. 2023;108:1835-1874.
    PubMed     Abstract available
    
    
    
88. TRINH A, Milat F
    Response to: Zoledronate Increases Bone Mineral Density in Nonambulant Children With Cerebral Palsy: A Randomized, Controlled Trial.
    J Clin Endocrinol Metab. 2023 Jul 12:dgad386. doi: 10.1210.
    PubMed    
    
    
    
89. JAISWAL R, Johansson H, Axelsson KF, Magnusson P, et al
    Hemoglobin levels improve fracture risk prediction in addition to FRAX(R) clinical risk factors and bone mineral density.
    J Clin Endocrinol Metab. 2023 Jul 5:dgad399. doi: 10.1210.
    PubMed     Abstract available
    
    
    June 2023
90. WATTS NB, Leslie WD
    Letter to the Editor from Watts and William: Comparisons between different anti-osteoporosis medications on postfracture mortality: a population-based study.
    J Clin Endocrinol Metab. 2023 Jun 2:dgad317. doi: 10.1210.
    PubMed    
    
    
    May 2023
91. GRANILD-JENSEN JB, Moller-Madsen B, Rackauskaite G, Farholt S, et al
    Zoledronate increases bone mineral density in non-ambulant children with cerebral palsy: A randomized, controlled trial.
    J Clin Endocrinol Metab. 2023 May 26:dgad299. doi: 10.1210.
    PubMed     Abstract available
    
    
    
92. CARBONE L, Buzkova P, Fink HA, Robbins JA, et al
    Plasma Levels of Branched Chain Amino Acids, Incident Hip Fractures and Bone Mineral Density of the Hip and Spine.
    J Clin Endocrinol Metab. 2023 May 18:dgad275. doi: 10.1210.
    PubMed     Abstract available
    
    
    
93. SKJODT MK, Abrahamsen B
    New insights in the pathophysiology, epidemiology and response to treatment of osteoporotic vertebral fractures.
    J Clin Endocrinol Metab. 2023 May 15:dgad256. doi: 10.1210.
    PubMed     Abstract available
    
    
    
94. HO-LE TP, Tran TS, Nguyen HG, Center JR, et al
    Genetic prediction of lifetime risk of fracture.
    J Clin Endocrinol Metab. 2023 May 11:dgad254. doi: 10.1210.
    PubMed     Abstract available
    
    
    
95. MEIER C, Eastell R, Pierroz DD, Lane NE, et al
    Biochemical Markers of Bone Fragility in Patients with Diabetes. A Narrative Review by the IOF and the ECTS.
    J Clin Endocrinol Metab. 2023 May 8:dgad255. doi: 10.1210.
    PubMed     Abstract available
    
    
    
96. MEIER C, Eastell R, Pierroz DD, Lane NE, et al
    Biochemical Markers of Bone Fragility in Patients With Diabetes.
    J Clin Endocrinol Metab. 2023 May 8:dgad255. doi: 10.1210.
    PubMed     Abstract available
    
    
    April 2023
97. PACCOU J, Badr S, Lombardo D, Khizindar H, et al
    Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women: The ADIMOS Case-Control Study.
    J Clin Endocrinol Metab. 2023 Apr 5:dgad195. doi: 10.1210.
    PubMed     Abstract available
    
    
    March 2023
98. FAN W, Leder BZ, Bolster MB
    Response to Letter to the Editor from Riahi and Gruntmanis: 'Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates'.
    J Clin Endocrinol Metab. 2023 Mar 22:dgad161. doi: 10.1210.
    PubMed    
    
    
    
99. RIAHI S, Gruntmanis U
    "Letter to the Editor from Riahi and Gruntmanis: 'Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates'.
    J Clin Endocrinol Metab. 2023 Mar 22:dgad162. doi: 10.1210.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Osteoporosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum